All In Biotech

NDA 202810 · Supernus Pharms

Oxtellar Xr

Oxcarbazepine · Oral · Anti-epileptic Agent

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Oct 19, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

62

13 Phase 3, 2 recruiting

FAERS reports

16,581

12,698 serious, 1,331 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

Oxtellar XR is indicated for the treatment of partial-onset seizures in patients 6 years of age and older. Oxtellar XR® is indicated for the treatment of partial-onset seizures in patients 6 years of age and older. ( 1 )

Mechanism: The pharmacological activity of Oxtellar XR is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine [see Clinical Pharmacology (12.3) ]. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of...

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • OXTELLAR XR · OXCARBAZEPINE 600MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • OXTELLAR XR · OXCARBAZEPINE 150MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • OXTELLAR XR · OXCARBAZEPINE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxcarbazepine" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,999
  • seizure1,461
  • off label use1,157
  • fatigue860
  • somnolence793
  • hyponatraemia746
  • dizziness727
  • headache715
  • drug interaction701
  • fall628
  • nausea594
  • anxiety514

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200464
200593
2006115
200794
2008208
2009332
2010301
2011378
2012459
2013434
2014438
2015671
2016887
2017894
20181,017
20191,172
20201,556
20211,317
20221,208
20231,308
20241,284
20251,337
20261,011

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxtellar XR (Oxcarbazepine)

2024 spending

$28.5M

Beneficiaries

2,844

18,806 claims

Per beneficiary

$10,008

$17.96 per unit

View as table
YearSpending
2020$23,476,116
2021$26,253,260
2022$29,025,925
2023$31,434,532
2024$28,461,792

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 339 on PubMed

Sponsor: Supernus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.